Paradigm Biopharmaceuticals (ASX:PAR) Buyback Yield %: -25.78 (As of Jul. 03, 2026)


ASX:PAR Paradigm Biopharmaceuticals Ltd ASX:PAR
26 GF Score
Price A$0.18
! 5 Warning Signs
View Full Analysis

What is Paradigm Biopharmaceuticals Buyback Yield %?

Paradigm Biopharmaceuticals ASX:PAR +2.94% 26 Buyback Yield % is -25.78 as of Jul. 03, 2026. GuruFocus rates ASX:PAR with a GF Score™ of 26/100. The stock has 5 warning signs investors should review. Among 744 Biotechnology companies, Paradigm Biopharmaceuticals ranks worse than 72.98% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Paradigm Biopharmaceuticals's current buyback yield was -25.78%.

Paradigm Biopharmaceuticals Buyback Yield % Related Terms

Paradigm Biopharmaceuticals Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Paradigm Biopharmaceuticals's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paradigm Biopharmaceuticals Buyback Yield % Chart

Paradigm Biopharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.21 0.00 -22.31 -31.65 -12.73

Paradigm Biopharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.98 -31.65 -10.34 -12.73 -12.51

ASX:PAR vs VRTX, REGN, ALNY: Buyback Yield % Comparison

For the Biotechnology subindustry, Paradigm Biopharmaceuticals's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Paradigm Biopharmaceuticals Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paradigm Biopharmaceuticals's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Paradigm Biopharmaceuticals's Buyback Yield % falls into.


ASX:PAR
26GF Score
Paradigm Biopharmaceuticals Ltd ASX:PAR
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Paradigm Biopharmaceuticals Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Paradigm Biopharmaceuticals's Buyback Yield for the fiscal year that ended in Jun. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (-0.882 + 16.001) / 118.775845
=-12.73%

Paradigm Biopharmaceuticals's annualized Buyback Yield for the quarter that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (-0.129 + 18.354) / 145.69646
=-12.51%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -25.78 mean?
Paradigm Biopharmaceuticals (ASX:PAR) has a Buyback Yield % of -25.78 as of Jul. 03, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Paradigm Biopharmaceuticals and its competitors. According to the industry distribution chart, Paradigm Biopharmaceuticals ranks #543 out of 744 companies in the Biotechnology industry, placing it in the top 73%.
Is Paradigm Biopharmaceuticals' Buyback Yield % too high?
Paradigm Biopharmaceuticals' current Buyback Yield % is -25.78. Based on the distribution chart, Paradigm Biopharmaceuticals ranks #543 out of 744 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Paradigm Biopharmaceuticals has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Paradigm Biopharmaceuticals' Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Paradigm Biopharmaceuticals ranks #543 out of 744 companies for Buyback Yield %. This places Paradigm Biopharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Paradigm Biopharmaceuticals and its competitors. Paradigm Biopharmaceuticals's current Buyback Yield % is -25.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paradigm Biopharmaceuticals stock overvalued right now?
Paradigm Biopharmaceuticals (ASX:PAR) has a current Buyback Yield % of -25.78. The current Buyback Yield % is -25.78. Paradigm Biopharmaceuticals' overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Paradigm Biopharmaceuticals (ASX:PAR), the current Buyback Yield % is -25.78 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Paradigm Biopharmaceuticals Business Description

Other Exchanges PBIGF:USAP86:Germany
Address 500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulfate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.
26GF Score

Get the complete analysis for ASX:PAR

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.18
Price